Department of Allergy and Medical Rhinology, Royal National Throat Nose & Ear Hospital, London, England.
Rhinology. 2013 Mar;51(1):9-17. doi: 10.4193/Rhino11.268.
Sublingual immunotherapy (SLIT) is now an established treatment for allergic rhinitis. Whilst several systematic reviews have now confirmed clinical efficacy and safety, recent analysis also confirms that therapeutic benefit persists for several years after the com- pletion of SLIT. Such findings, along with the obvious ease of administration of sublingual preparations, have clearly promoted SLIT as an attractive option for treatment of allergic rhinitis resistant to medical treatment. This article reviews the development, efficacy and safety of SLIT in allergic rhinitis and the current indications for its use.
舌下免疫疗法 (SLIT) 现已成为治疗过敏性鼻炎的一种既定方法。尽管有几项系统评价现已证实了其临床疗效和安全性，但最近的分析也证实，在 SLIT 完成后，其治疗益处仍可维持数年。这些发现，再加上舌下制剂使用的明显便利性，无疑促进了 SLIT 成为治疗对药物治疗有抗性的过敏性鼻炎的一种有吸引力的选择。本文综述了 SLIT 在过敏性鼻炎中的发展、疗效和安全性，以及其目前的适应证。
